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Abstract
Both the MAP kinase and PI3K/Akt pathways play an important role in the pathogenesis of melanoma. We conducted the
present study to test the hypothesis that targeting the two pathways to potently induce cell inhibition accompanied with
thyroid iodide-handling gene expression for adjunct radioiodine ablation could be a novel effective therapeutic strategy for
melanoma. We used specific shRNA approaches and inhibitors to individually or dually suppress the MAP kinase and PI3K/
Akt pathways and examined the effects on a variety of molecular and cellular responses of melanoma cells that harbored
activating genetic alterations in the two pathways. Suppression of the MAP kinase and PI3K/Akt pathways showed potent
anti-melanoma cell effects, including the inhibition of cell proliferation, transformation and invasion, induction of G0/G1 cell
cycle arrest and, when the two pathways were dually suppressed, cell apoptosis. Remarkably, suppression of the two
pathways, particularly simultaneous suppression of them, also induced expression of genes that are normally expressed in
the thyroid gland, such as the genes for sodium/iodide symporter and thyroid-stimulating hormone receptor. Melanoma
cells were consequently conferred the ability to take up radioiodide. We conclude that dually targeting the MAP kinase and
PI3K/Akt pathways for potent cell inhibition coupled with induction of thyroid gene expression for adjunct radioiodine
ablation therapy may prove to be a novel and effective therapeutic strategy for melanoma.
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Introduction
Melanomaisacommonskincancerandrecentdecadeshaveseen
a markedly increase in its incidence worldwide [1–3]. In the United
States alone, 62,480 new cases and 8,420 deaths from melanoma
wereestimatedfortheyearof2008 [3].Althoughearly-stage disease
is curable through surgical excision, advanced metastatic melanoma
is resistant to current treatments, with a rapidly progressive course
and high mortality rate [4,5]. A major effort in melanoma research
has thus been to identify novel treatment strategies targeting major
molecular pathways, particularly the Ras R Raf R MEK R MAP
kinase/ERK (MAPK)and PI3K/Aktsignalingpathways,whichare
commonly over-activated by genetic alterations, such as the BRAF
mutations in the MAPK pathway [6] and the PIK3CA amplification
and PTEN mutations in the PI3K/Akt pathway [7–9]. These two
pathways play a fundamental role in the pathogenesis and
progression of melanoma and are therefore important therapeutic
targets for this cancer [10–15].
Radioiodinetherapybasedonthesodium/iodidesymporter(NIS)
gene transfer has been widely investigated as a potential therapeutic
strategy for extrathyroidal malignancies [16–20]. NIS is normally
expressed in the basal membrane of follicular thyroid cells, which
transports iodide from blood stream into the cell for the biosynthesis
of thyroid hormone [18,21]. This process also involves several other
key molecules, including thyroglobulin (Tg), which incorporates
iodide through organification that involves thyroperoxidase (TPO).
Thyroid transcription factor 1 (TTF1 or TITF1) and 2 (TTF2 or
FOXE1) and PAX8 are involved in the regulation of these genes.
Expressionofmanyoftheseiodide-handlinggenesinthethyroidcell
is up-regulated by the thyroid-stimulating hormone (TSH), which
actsontheTSHreceptor(TSHR)inthethyroidcellmembrane.This
is the molecular basis for the commonly used radioiodide ablation
therapyforthyroidcancer,whichisclinicallyfacilitatedbyincreasing
the level of TSH in the blood of the patient either through thyroid
hormonewithdrawaloradministrationofrecombinanthumanTSH
[22,23]. In papillary thyroid cancer (PTC), BRAF mutation (and
hence activation of the MAPK pathway) was associated with
decreased radioiodine avidity [24–26], which can be explained by
BRAF mutation-associated silencing of thyroid iodide-handling
genes, such as NIS [18,27], Tg [27], and TPO [26–29]. Several
previous studies also demonstrated involvement of the PI3K/Akt
pathway in the regulation of thyroid iodide-handling genes. For
example, expression of a mutant Ras that selectively stimulated the
PI3K/Akt pathway markedly decreased TSH-induced NIS expres-
sion [30] and IGF-I could inhibit cAMP-induced NIS expression
through activating the PI3K/Akt pathway in thyroid cells [31].
In recent clinical trials on various human cancers, including
melanoma, targeting an individual pathway, such as the MAPK
pathwayorthe PI3K/Aktpathway,orusing asingleagentgenerally
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suggest that targeting multiple signaling pathways is a necessary
therapeutic strategy for melanoma. Interestingly, a recent study
showed common expression of TSHR in melanoma cells, but no or
little expression in benign skin lesions [33], raising the possibility
that otherthyroidiodide-handlinggenesmightalsobeexpressiblein
melanoma cells. In the present study, we tested the therapeutic
potential of dually targeting the MAPK and PI3K/Akt pathways in
melanoma cells for synergistic/additive cell inhibition coupled with
thyroid iodide-handling gene expression and radioiodide uptake as
a novel therapeutic strategy for melanoma.
Results
Synergistic/additive inhibition of cell proliferation and
induction of thyroid iodide-handling gene expression in
melanoma cells by dually suppressing the MAPK and
PI3K/Akt pathways using specific inhibitors
We first used the melanoma cell line NPA cell, a cell clone
derived from the melanoma cell line M14 cell [34], and inhibitors
of the MAPK and PI3K/Akt pathways to test the therapeutic
potential for melanoma of dully targeting the two pathways to
induce potent cell inhibition coupled with thyroid iodide-handling
gene expression for potential radioiodide treatment. As shown in
Figure 1A, treatment of cells with the MEK inhibitor U0126 and
the Akt inhibitor IV (Akti IV) [35] strongly inhibited phosphor-
ylation of ERK (p-ERK) and Akt (p-Akt), respectively. Corre-
spondingly, the two inhibitors inhibited cell proliferation partially
when used individually and virtually completely when used in
combination (Figure 1B). To explore the ability of suppressing the
MAPK and PI3K/Akt pathways to induce the expression of
iodide-metabolizing genes in melanoma cells, we tested the effects
of U0126 and Akti IV on NPA cells which had no or low basal
expression of iodide-handling genes. As shown in Figure 1C,
expression of several iodide-handling genes, including NIS, TSHR,
Tg, and TTF1, was induced or dramatically enhanced after
treatment of cells with U0126 or Akti IV, particularly U0126.
Similar effects of these inhibitors of the MAPK and PI3K/Akt
pathways on cell inhibition and iodide-handling gene expression
were seen in DRO cells (data not shown). This phenomenon of
Figure 1. Effects of suppression of the MAPK and PI3K/Akt pathways by specific inhibitors on NPA cells. A) Inhibition of ERK and Akt
phosphorylation by suppression of MAPK and PI3K/Akt pathways using the MEK-specific inhibitor U0126 and the Akt-specific inhibitor Akti IV,
respectively. NPA cells were treated with U0126 at 10 mM, or with Akti IV at 0.5 mM for 30 h. DMSO was used as vehicle control. Cells were lysed for
Western blotting assay. The activities of MAPK and PI3K/Akt pathways were reflected by the level of phosphorylated ERK and Akt detected with
specific anti-phosphorylated ERK (p-ERK) and anti-phosphorylated Akt (p-Akt) antibodies. Immunoblotting with antibody against b-actin was used for
quality control. B) Inhibition of cell proliferation by suppression of MAPK and PI3K/Akt pathways achieved with U0126 and Akti IV individually or in
combination (U+A) as indicated. MTT assay was performed to evaluate cell proliferation over a 5-day course of treatment with U0126 and Akti IV. NPA
cells were treated with 4 mM U0126 and 0.2 mM Akti IV, respectively – lower concentrations than those in A) were used for the two inhibitors in order
to examine their additive/synergist effects. C) Expression of thyroid genes by dual suppression of MAPK and PI3K/Akt pathways using U0126 and Akti
IV. For expression analysis of thyroid genes (NIS, TSHR, Tg, TPO, FOXE1, and TTF1), total RNA was isolated and RT-PCR was performed after cells were
treated with U0126 and Akti IV individually or combination at the concentrations used in A) for 30 h.
doi:10.1371/journal.pone.0006200.g001
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investigated using the real-time quantitative RT-PCR approach in
subsequent studies as described below.
Expression of iodide-handling genes in various
melanoma cell lines induced by suppressing the MAPK
and PI3K/Akt pathways and its enhancement or synergy
by TSH stimulation
Encouraged by the novel finding of the expression of iodide-
handling genes upon suppression of the MAPK and PI3K/Akt
pathways in the NPA cell, we extended this study to other
melanoma cell lines. As shown in Figure 2, in several melanoma
cell lines tested, including M14, UACC62, A-375 and, again, NPA
cells, dually suppressing the MAPK and PI3K/Akt pathways by
U0126 and Akti IV showed synergistic/additive effects on the
expression of most of the iodide-handling genes compared with
suppressing either pathway alone. Since TSHR plays an important
role in up-regulating the iodide-handling genes in thyroid cells
[21] and is expressed in melanoma cells upon suppression of the
MAPK and PI3K/Akt pathways, we investigated whether TSH
treatment could affect the expression of iodide-handling genes in
melanoma cells. Remarkably, treatment of melanoma cells with
TSH enhanced or synergized the expression of many of the iodide-
handling genes induced either by suppression of one signaling
pathway alone or simultaneous suppression of both pathways
(Figure 2). This effect of TSH seemed to be most commonly
evident when the MAPK pathway was suppressed.
Figure 2. Effect of TSH stimulation on expression of thyroid genes mediated by suppressing MAPK and PI3K/Akt pathways,
individually or in combination, in melanoma cells. Melanoma cells, as indicated, were treated with specific inhibitors (U0126 and Akti IV) as
described in Figure 1. Before RNA was extracted, cells were treated with 40 mU/ml TSHb for 6 h. Details are described in the Materials and Methods.
Data are presented as the mean6SD of values from three assays. In comparison with control, *, P,0.05; **, P,0.01.
doi:10.1371/journal.pone.0006200.g002
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knockdown of BRAF and Akt-1/2
The above findings from the experiments using pharmacolog-
ical inhibitors strongly suggest that dually targeting the MAPK
and PI3K/Akt signaling pathways to induce both cellular
inhibition and thyroid gene expression for adjunct radioiodine
ablation therapy could be a novel and effective therapeutic
strategy for melanoma. To more specifically test this hypothesis, in
the next series of experiments, we used siRNA approaches to
specifically knock down the MAPK and PI3K/Akt pathways,
individually or dually in a selected melanoma cell line, the NPA
cell. We pursued stable transfection with dual knockdown of Akt-1
and Akt-2 in combination with BRAF knockdown to achieve dual
suppression of the two signaling pathways. To this end, we stably
transfected NPA cells with pSicoR-PGK-puro encoding specific
shRNA homologue sequences for Akt-1 and Akt-2 (Akt-1/2),
superimposed with or without stable transfection of specific BRAF
siRNA. Cells stably infected with lentivirus expressing BRAF and
Akt-1/2 siRNA were successfully selected using puromycin, as
demonstrated by effective suppression of expression of the
corresponding proteins. Specifically, as shown in Figure 3A,
BRAF and Akt-1/2 siRNA stably and virtually completely
inhibited the expression of BRAF and Akt-1/2, respectively,
compared with empty vectors. As shown in Figure 3B and C,
specific BRAF siRNA strongly inhibited proliferation and
transformation of cells, the latter being reflected by anchorage-
independent colony formation on soft agar. Similarly, specific Akt-
1/2 siRNA also exhibited dramatic inhibition of cell proliferation
and transformation (Figure 3B and C). Further inhibition of cell
proliferation and transformation was achieved by dual knockdown
of BRAF and Akt-1/2 (Figure 3B and C). Migration/invasion of
the NPA cells on Matrigel was also inhibited by stable siRNA
knockdown of either pathway, with further inhibition achieved
with dual knockdown of the two pathways (Figure 4).
Figure 3. Effects of stable siRNA knockdown of BRAF and Akt-1/2, individually or dually, on cell proliferation and colony formation.
A) NPA cells were infected with lentivirus expressing BRAF or Akt-1/2 siRNAs or both and stable populations were selected with 2 mg/ml puromycin.
The empty vector was used as the control. After a 2-week selection, cells were lysed and immunoblotted with BRAF, Akt-1 and Akt-2 antibodies. The
antibody against b-actin was used for quality control of Western blotting. B) Proliferation rate of NPA cells stably transfected with various siRNA
constructs as described in A) was measured with MTT assay daily over a 5-day course. Results are expressed as means6SD of three independent
experiments. C) Representative results of colony formation in soft agar of thyroid cancer cells with stable transfections with different siRNA
constructs, including empty vector (vector), BRAF siRNA (BRAF KD), Akt-1/2 siRNA (Akt-1/2 KD), and combination of Akt-1/2 and BRAF siRNA
(BRAF+Akt-1/2 KD). Data represent means6SD of three independent experiments. KD, knockdown (same as in all other Figures).
doi:10.1371/journal.pone.0006200.g003
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siRNA knockdown of BRAF and Akt-1/2
To investigate further the cellular events involved in the
inhibition of cell proliferation by dual suppression of MAPK and
PI3K/Akt pathways, we transiently transfected BRAF and Akt-1/
2 siRNA in NPA cells and measured cell cycle and apoptotic
patterns by flow cytometric analysis of DNA content and Annexin
V expression (Figure 5). Compared with control vector, siRNA
knockdown of BRAF and Akt-1/2 caused an increase in the G0/
G1 fraction from 62.862.4% to 78.862.2% (P,0.01) and to
7162.4% (P,0.05), respectively (Figure 5A). With dual knock-
down of BRAF and Akt-1/2, there was a dramatic synergistic
increase in the sub-G0 fraction in comparison with control vector
(8.161.1% vs. 0.660.2%, P,0.001) or knockdown of BRAF
(8.161.1% vs. 0.860.2%, P,0.001) or Akt-1/2 (8.161.1% vs.
1.160.3%, P,0.001) alone, reflecting increased cell apoptosis,
and the G0/G1 fraction was correspondingly only moderately
increased (Figure 5A). These data were consistent with the
apoptotic patterns shown in Figure 5B, which showed a dramatic
increase in both early and late apoptosis with dual knockdown of
BRAF and Akt-1/2 in comparison with control vector (8.560.9%
vs. 1.160.4%, P,0.001; 11.961.4% vs. 3.860.6%, P,0.01),
respectively. In contrast, knockdown of BRAF or Akt-1/2 alone
had a much smaller effect on cell apoptosis. These data suggest
that both increased G0/G1 cell cycle arrest and cell apoptosis were
involved in the inhibition of NPA cell growth by suppression of
MAPK and PI3K/Akt pathways. The effects were most significant
with dual knockdown of the MAPK and PI3K/Akt pathways,
particularly for cell apoptosis.
NIS protein expression and radioiodide uptake in
melanoma cells induced by suppressing the MAPK and
PI3K/Akt pathways
As NIS plays the most important role in cellular iodide uptake,
we next explored further the effect of suppressing the MAPK and
PI3K/Akt pathways on NIS expression in melanoma cells. As
shown in Figure 6A, stable knockdown of BRAF and/or Akt-1/2
with specific siRNA induced the expression of NIS in NPA cells,
consistent with the results achieved with treatments of cells with
pharmacological inhibitors (Figure 1C and Figure 2). We next
investigated the effects of suppressing the MAPK and PI3K/Akt
pathways on the expression of NIS protein in NPA cells. As shown
in Figure 6B, U0126 and Akti IV increased the NIS expression
from 1.1+2.3% to 2.8+3.2% and 6.5+7.2%, respectively, and to
12+7.0% with combination of the two (Figure 6B, upper panel).
Although both U0126 and Akti IV induced NIS protein
expression, Akti IV showed a more pronounced effect (Figure 6B,
upper panel). Combination of U0126 and Akti IV showed
significantly enhanced or synergized effects on NIS protein
expression (Figure 6B, upper panel). Similarly, siRNA knockdown
of BRAF and Akt-1/2 could each increase the NIS protein
expression, albeit modestly, and dual knockdown of BRAF and
Akt-1/2 showed enhanced effects (Figure 6B, lower panel). We
also performed immunofluorescent microscopy, which showed
that dual inhibition of the MAPK and PI3K/Akt pathways by
U0126 and Akti IV robustly induced the expression of NIS protein
on cell membranes (Figure 6C).
Given the induction of expression of iodide-handling genes in
melanoma cells by suppression of the MAPK and PI3K/Akt
pathways, we finally examined functionally the ability of these cells
to take up radioiodide. As shown in Figure 6D, treatment of NPA
cells with U0126 or Akti IV significantly increased radioiodide
uptake and combination of the two inhibitors resulted in an
enhanced uptake. Stable knockdown of BRAF or Akt-1/2 could
also increase radioiodide uptake, which was enhanced by
simultaneous knockdown of the two.
Discussion
Recent advances in understanding aberrant signaling of
molecular pathways in melanoma provide the bases for the
Figure 4. Effects of stable siRNA knockdown of BRAF and Akt-1/2, individually or dually, on the invasion of NPA cells. Invading rate of
cells stably transfected with specific siRNAs constructs to knock down BRAF and Akt-1/2, individually or dually, as described in Figure 3 was measured
using Matrigel-coated transwell cell culture chambers. A) Shown are representative results of invasive NPA cells. B) The bar graphs, corresponding to
(A), show means6SD of the numbers of invading cells from three independent experiments.
doi:10.1371/journal.pone.0006200.g004
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particular importance are the MAPK and PI3K/Akt pathways,
which, through their genetic alterations, play a critical role in the
development and pathogenesis of melanoma and are therefore
tested vigorously as important therapeutic targets for this cancer
[6,10–15]. Several clinical trials targeting these pathways in
various cancers, including melanoma, have been recently
completed [9,15,32]. Disappointingly, however, little or no anti-
tumor response has been achieved in these trials, which were
single-agent based and, hence, targeted limited pathways. It
becomes increasingly questionable whether targeting only single or
limited pathways is an effective therapeutic strategy for cancers
[15,32]. Given the importance of both the MAPK and PI3K/Akt
pathways in melanoma, simultaneously targeting the two path-
ways, instead of either alone, may prove to be a particularly
effective therapeutic strategy for this cancer. In the present study,
we tested this hypothesis by dually and specifically suppressing the
MAP kinase and PI3K/Akt pathways in melanoma cells and
examining molecular and cellular consequences. Our main theme
in this effort was to particularly test a novel therapeutic strategy of
inducing both potent cellular inhibition and thyroid iodide-
handling gene expression for potential adjunct radioiodide therapy
for melanoma.
In addition to using specific inhibitors of the pathways, we used
shRNA approaches to simultaneously and specifically knock down
Akt-1/2 and BRAF, resulting in synergistic/additive inhibition of
melanoma cell proliferation, colony formation and invasion, as
well as apoptosis. Due to the technical complexities and laborious
efforts required in shRNA approaches for simultaneous knock-
down of multiple signaling pathways, previous studies on certain
cancer cell lines, including one in melanoma cells [14], only
attempted using drug inhibitors for simultaneous suppression of
the MAPK and PI3K/Akt pathways. The present study represents
the first to use the shRNA approach to simultaneously and
specifically knock down the MAPK and PI3K/Akt signaling in
cancer cells, definitely demonstrating the therapeutic potential of
dually targeting the two pathways for cancers, such as melanoma.
Of particular note in the present study is that although suppression
of either the MAPK or PI3K/Akt pathway could cause significant
inhibition of melanoma cell proliferation, suppression of either
alone caused little cell apoptosis. Previous studies targeting single
pathways using single agents also only showed cell cycle arrest at
Figure 5. Effects of siRNA knockdown of BRAF and Akt-1/2, individually or dually, on G0/G1 cell cycle arrest and apoptosis of NPA
cells. NPA cells were transiently transfected with specific siRNAs to knock down BRAF and Akt-1/2, individually or dually as indicated. After a 4-day
culture, DNA content (A) was measured by flow cytometry to determine cell cycle fractions. The fraction of apoptotic cells (sub-G0) is indicated (A).
Cell apoptosis (B) was measured by Annexin V staining and flow cytometry. The right lower quadrant of each plot contains early apoptotic cells,
whereas the right upper quadrant contains late apoptotic cells. Details are described in the Materials and Methods.
doi:10.1371/journal.pone.0006200.g005
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radioiodine uptake in NPA cells. A) NPA cells were stably transfected with specific siRNAs to knock down BRAF and Akt-1/2, individually or dually
as described in Figure 3. After a serum starvation for 24 h, total RNA was isolated for expression analysis for the indicated thyroid iodide-metabolizing
genes. RT-PCR analysis was performed for the expression of NIS in NPA cells. B) Flow cytometric measurement of NIS protein expression. NPA cells
were treated with specific inhibitors (upper panel) as described in Figure 1 or stably transfected with specific siRNAs to knock down BRAF and Akt-1/
2, individually or in combination as described in Figure 3 (lower panel). NIS protein levels were measured by flow cytometry. The blue frames indicate
the cells expressing NIS protein, including dead (right upper quadrant; positive for both 7-AAD and NIS) and living (right lower quadrant, positive
Thyroid Genes and Melanoma
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These results are consistent with the recent clinical trials on
melanoma using single agents that showed little anti-tumor effect
other than only tumor stability in some cases [9,15,32].
Remarkably, the present study showed that combined suppression
of the MAPK and PI3K/Akt pathways synergistically promoted
cell apoptosis, suggesting that both pathways need to be removed
to induce melanoma cell death. This result is consistent with an
interesting previous observation that either pathway was sufficient
to protect melanoma cells from anoikis, a type of apoptosis
induced by loss of normal cell contact [38]. Thus, therapeutic
approaches dually targeting the MAPK and PI3K/Akt pathways
are likely to be more effective in killing melanoma cells harboring
genetic alterations that activate both pathways. Consequently, it
may be expected that a clinical trial using combined agents
targeting both the MAPK and PI3K/Akt pathways would likely
show significant anti-melanoma effectiveness, unlike the recently
completed single agent-based clinical trials [9,15,32]. Although
apoptosis was induced in a large portion of melanoma cells by
simultaneously targeting MAPK and PI3K/Akt pathways, it did
not seem to occur in all cells, suggesting that some alternative
pathways may also be involved.
Radioiodine ablation therapy is an effective and standard
treatment for thyroid cancer, which is routinely administered after
thyroidectomy in most thyroid cancer patients [22,23,39,40]. This
treatment takes advantage of the unique iodide-handling machin-
ery in thyroid cells, involving several key molecules, such as NIS,
TSHR, TPO, Tg, and several thyroid transcription factors. These
genes are frequently silenced in thyroid cancer, particularly in
association with aberrant activation of the MAPK and PI3K/Akt
pathways [18,26–29,41]. Suppression of the MAPK and PI3K/
Akt pathways could partially restore the expression of thyroid
iodide-handling genes in thyroid cancer cells [36, and Hou and
Xing, unpublished data]. A previous study interestingly showed
that melanoma cells also expressed TSHR [33]. Based on these
data, we suspected that melanoma cells might have the ability to
express other thyroid iodide-handling genes that were regulated by
the MAPK and PI3K/Akt pathways. This was proven to be the
case in the present study. In fact, we demonstrated that
suppression of either of the two pathways could induce the
expression of some thyroid iodide-handling genes and dual
suppression of the two pathways had a synergistic/additive effect
on their expression in melanoma cells. As an example, NIS, the
most important molecule involved in thyroid cellular uptake of
iodide, was robustly expressed in the cell membrane with dual
suppression of the MAPK and PI3K/Akt pathways either using
inhibitors or specific shRNA approaches. As in normal thyroid
cells, TSH significantly enhanced the expression of these genes
induced by suppression of the MAPK and PI3K/Akt pathways in
melanoma cells. Importantly, we also demonstrated that expres-
sion of thyroid iodide-handling genes effectively conferred
melanoma cells the ability to take up radioiodide. These results
have important novel therapeutic implications for melanoma:
radioiodide ablation, as in thyroid cancer, might be therapeutically
effective for melanoma in conjunction with the use of agents to
inhibit the MAPK and PI3K/Akt pathways. For radioiodide
treatment of thyroid cancer, TSH is routinely raised either by
thyroxine withdrawal or administration of human recombinant
TSH to enhance radioiodide uptake and ablation of thyroid
cancer cells [21,23,39,40]. This strategy could be similarly used for
melanoma given the expression of TSHR induced by suppressing
the MAPK and PI3K/Akt pathways and the enhancement of
expression of other iodide-metabolizing genes by TSH in
melanoma cells demonstrated in the present study. In recent
years, NIS gene transfer therapy to confer non-thyroid cancers the
sensitivity to radioiodide ablation therapy has been widely
investigated as a potential therapeutic strategy for human cancers
[18,42,43]. Yet, the technical complexities, inadequate therapeutic
efficiencies, and other issues associated with NIS gene transfer
have so far prevented it from rapid and successful clinical use. Our
demonstration of the induced expression of thyroid iodide-
handling genes and radioiodide uptake in melanoma cells opened
the possibility for a potentially safe, effective, and easy alternative
approach to therapeutic use of radioiodide in melanoma. Given
the results in the present study, it is attractive to propose clinical
trials to test the novel therapeutic strategy of simultaneously
targeting the MAPK and PI3K/Akt pathways for both synergis-
tic/additive cellular inhibition and thyroid gene expression for
adjunct radioiodide treatment in melanoma. Such clinical trials
are feasible particularly given the current availability of several
safe and potent inhibitors of the MAPK and PI3K/Akt pathways,
such as the MEK and Akt inhibitors [9,15,32].
Materials and Methods
Human melanoma cell lines
ThemelanomacelllineUACC62wasobtainedfromtheNational
Cancer Institute (NCI); melanoma cells lines M14 and A375 were
obtained from American Type Culture Collection (ATCC). The
NPA cell and DRO cell were provided by Dr. Guy J.F. Juillard
(University of California-Los Angeles School of Medicine, Los
Angeles,CA).Thesetwocelllineswerepreviouslymistakenlylabeled
as thyroid cancer cell lines [44] and have now been demonstrated to
be clones derived from the melanoma cell lines M14 and A375,
respectively [34]. NPA, M14 and UACC62 cells harbor genetic
alterations that can activate both the MAPK and PI3K/Akt
pathways: BRAF V600E mutation and PIK3CA amplifications in
NPA and M14 cells, and BRAF V600E mutation and inactivating
PTEN mutations (homozygous) in UACC62 cells. A375 and DRO
cellsharborBRAFV600Emutation.Cellswereculturedaspreviously
described[44,45].CellsweretreatedwiththeMEKinhibitorU0126
(Sigma) at 10 mM or Akt inhibitor IV (Akti IV, Calbiochem) at
0.5 mM for 30 h. DMSO was used as the vehicle control. In some
experiments as indicated, cells were additionally treated with bovine
TSH (TSHb) (Sigma) to test its effect on gene expression.
only for NIS) cells. C) Immunofluorescent localization of NIS. After a 30-h combined treatment with both U0126 and Akti IV (as in B), cells were
analyzed by immunofluorescent microscopy using anti-NIS and FITC-coupled secondary antibody and double immunofluorescence with the red color
representing 7-AAD nuclear staining and the green color representing NIS expression and localization. Cells marked with dash circles are intact living
cells that do not have 7-AAD nuclear staining. NIS staining in these cells represents NIS protein expression exclusively on the cell membrane. Cells
marked with solid circles show double colors, suggesting that the cells were not intact and therefore both cell membrane NIS staining and 7-AAD
nuclear staining occurred. The NIS expression is in striking contrast with the control cells which did not show any NIS staining even in the broken cells
that showed nuclear staining (red color) with 7-ADD. D) In vitro radioiodide uptake. NPA cells were treated with specific inhibitors or stably
transfected with various siRNA constructs as indicated. Cells were subsequently incubated with 1 mCi
125I/0.5 ml/well on 12-well plates for 1 h. Cells
were then washed and harvested for radioactivity measurement using a gamma-counter as described in the Materials and Methods. Data are
expressed as the mean6SD of values from three assays. **, P,0.01, compared with control or empty vector.
doi:10.1371/journal.pone.0006200.g006
Thyroid Genes and Melanoma
PLoS ONE | www.plosone.org 8 July 2009 | Volume 4 | Issue 7 | e6200Western blotting assay
Cells were lysed in Radio Immuno Precipitation Assay (RIPA)
buffer. Cellular proteins were resolved by electrophoresis on a
SDS-polyacrylamide (10%) gel (SDS-PAGE), transferred onto
Polyvinylidene Fluoride (PVDF) membranes (Amersham Pharma-
cia Biotech, Piscataway, NJ), and immunoblotted with specific
primary antibodies. Anti-BRAF (Sc-166), anti-phospho-AKT (Sc-
7985-R), anti-phospho-ERK (Sc-7383), and anti-Actin (Sc-1616-
R) were purchased from Santa Cruz (Santa Cruz, CA). Anti-Akt-1
(#2967) and anti-Akt-2 (#2964) were purchased from Cell
Signaling Technologies, Inc. (Beverly, MA). Antigen-antibody
complexes were visualized using HRP-conjugated anti-mouse (Sc-
2005, Santa Cruz, CA) or anti-rabbit (Sc-2004, Santa Cruz, CA)
IgG antibodies and ECL Western Blotting Analysis System
(Amersham Pharmacia).
RNA extraction, RT-PCR analysis, and real-time
quantitative RT-PCR analysis
Total RNA was isolated using TRIzol reagent according to
the instructions of the manufacturer (Invitrogen). Normal human
thyroid RNA samples purchased from Stratagene (La Jolla, CA)
were used as a positive control. RNA samples were quantified
using Multiskan Spectrum (Thermo, Electron Corporation) prior
to use. The A260/A280 ratios were between 1.8 and 2.0. Two
mg of total RNA was converted to cDNA on an iCycler
Thermal Cycler (Bio-Rad) using Oligo-dT and SuperScript II
according to the instructions of the manufacturer (SuperScript
First-Strand Synthesis kit, Invitrogen). Conventional RT-PCR
amplification was carried out to amplify NIS, TSHR, Tg, TPO,
FOXE1, and TTF1. The a ˆ-actin gene was run in parallel for
quality control. The primer sequences were presented in
Supplementary Table S1 and 0.4 mM each primer was used in
each reaction. PCR products were resolved by 1.5% agarose gel
electrophoresis and visualized by ethidium bromide staining.
Real-time quantitative RT-PCR analysis was performed to
evaluate expression of thyroid genes on an ABI Prism
7900HT Sequence Detector (Applied Biosystems), using SYBR
GreenER qPCR SuperMix according to the instructions of the
manufacturer (Applied Biosystems). This reaction mixture
contained AmpErase (UNG). The expression value of each gene
was normalized to a ˆ-actin cDNA to calculate the relative
amount of RNA present in each sample according to the 2
2DDCt
method [46]. b-actin is a commonly used reference gene for the
type of analysis we performed. We also tested other two
frequently used reference genes, GAPDH and HPRT1, in some
experiments and found similar results for the expression of
thyroid genes, suggesting that b-actin is a valid normalizer in the
present study. Each sample was run in triplicate. The primers of
intron-spanning thyroid-specific genes, NIS, TSHR, Tg, TPO,
FOXE1, and TTF1 were designed using Primer Express (Applied
Biosystems, CA) following the recommended guidelines based on
sequences from GenBank. The primer sequences are presented
in Supplementary Table S2 and 0.25 mM each primer was used
in the reaction. The specificity of real-time quantitative PCR for
all these genes was confirmed by running the PCR products on
a 1.5% agarose gel to show single specific bands of the PCR
products at the expected sizes (Supplementary Figure S1),
followed by direct sequencing of the PCR products using Big
Dye terminator V 3.0 cycle sequencing reagents (Applied
Biosystems, Foster City, CA). The sequences of the real-time
quantitative PCR products were confirmed to represent the
correct genes (Supplementary Figure S2). The reliability of the
real-time quantitative PCR was also assured by the nearly
perfect standard curves established using serial dilutions of
normal human thyroid cDNA for all these genes (Supplementary
Figure S3). The copy number of cDNA analyzed using this real-
time quantitative PCR technique for each gene was therefore
reliable in the present study.
Lentivirus-mediated RNA interference of BRAF, Akt-1, and
Akt-2
The lentiviral pSicoR-PGK-puro vectors (Addgene Inc. Cam-
bridge, MA, USA) encoding hairpin RNA sequences were used to
knock-down BRAF and specific Akt isoforms. The hairpin
sequences used for BRAF and combined Akt-1 and Akt-2 (Akt-
1/2) were presented in Supplementary Table S3. To generate
lentiviral particles, human embryonic kidey 293 cells (ATCC,
Manassas, VA, USA) were co-transfected with the lentiviral vector
and compatible packaging plasmid mixture using Lipofectamine
2000 (Invitrogen), following the manufacturer’s instructions.
Melanoma cells were exposed to lentivirus-containing supernatant
for 16 hours in the presence of Polybrene (Sigma). After 3–4 days,
the cells were serum-starved (0.5% FBS) and harvested 24 hours
later in RIPA lysis buffer (Santa Cruz, CA). Western blotting
assays were used to detect the protein expression of BRAF, Akt-1,
and Akt-2.
Cell proliferation assay
Cells (800/well) were seeded into 96-well plates and cultured
with 2.5% FBS. MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyl-
tetrazolium Bromide] assay was performed daily over a 5-day time
course to evaluate cell numbers using a MTT cell proliferation
assay kit (ATCC, Manassas, VA, USA) following the manufac-
turer’s instructions.
Colony formation assay
For soft-agar colony-formation assay, 1610
5 cells were plated
into 6-well plates with a bottom layer of 0.6% agar and a top layer
of 0.3% agar. Following the hardening of soft agar, plates were
incubated at 37uC with 5% CO2. After 2–3 weeks of culture,
colonies were counted and photographed automatically by an
AlphaImager Imaging System (Alpha Innotech).
Cell invasion assay
Cell invasion was assayed in triplicates using Matrigel-coated
Transwell cell culture chambers (#354481, BD Biosciences).
Briefly, cells (1.5610
5 cells/well) suspended in serum-free medium
were placed in the upper chamber of the Transwell insert, and
RPMI 1640 medium containing 10% FBS was added to the lower
chamber. Following a 24 h-incubation at 37uC with 5% CO2,
non-invasive cells in the upper chamber were removed and
invasive cells were fixed in 100% methanol and stained with 0.5%
crystal violet in 2% ethanol. The numbers of invasive cells were
automatically counted and photographed by an AlphaImager
Imaging System (Alpha Innotech).
Cell cycle analysis
Cells were harvested, washed twice in PBS, and resuspended
in 70% ethanol on ice for at least 30 min. After centrifugation,
1610
6 cells transiently transected with various siRNA con-
structs were resuspended in 1 ml of propidium iodide staining
solution (50 mg of propidium iodide, 1 mg of RNase A, and
1 mg of glucose per 1 ml PBS) and incubated at room
temperature for 30 min. Cell cycles were analyzed based on
DNA contents by FACS using a LSR Flow Cytometer (BD
Biosciences, NJ).
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Cells were transiently transfected with various siRNA con-
structs. After a 24-h serum starvation, cells were harvested, washed
with PBS, and subjected to sequential staining with Annexin V-PE
Apoptosis Detection Kit (BD Biosciences) by two-color flow
cytometry, according to the manufacturer’s protocol. Cells that
were Annexin V-positive and 7-AAD-negative served as early
apoptotic population. Cells that were both Annexin V- and 7-
AAD-positive served as late apoptotic population.
Flow cytometry analysis of NIS expression
Cells treated with specific inhibitors and various siRNA
constructs to induce the expression of NIS were incubated with
VJ2 a-hNIS mAb (a gift from Dr. Sabine Costagliola at the Free
University of Brussels) [47] diluted at 1:20 in FACS buffer (3%
FBS, 0.02% NaN3 in PBS) at 4uC for 1 h. Cells were then washed
once with FACS buffer and incubated with FITC-conjugated a-
mouse IgG (Sigma) diluted at 1:100 in FACS buffer at 4uC for 1 h.
Cells were washed again in FACS buffer, resuspended in 2 ml of
FACS buffer with 7-AAD, and analyzed by FACS using a LSR
Flow Cytometer (BD Biosciences, NJ). Secondary antibody alone
was used as a negative control. Fluorescent microscopic examina-
tion was conducted to monitor NIS expression (Nikon Corpora-
tion, Tokyo, Japan).
Radioactive iodine uptake assay
Cells (1610
6 cells/well) treated under the indicated conditions
were seeded in 12-well plates. Cells in 0.5 ml/well were incubated
with RPMI 1640 medium containing 1 mCi Na
125I and 5 mM
non-radioactive NaI for 1 h at 37uC with 5% CO2. The medium
was subsequently aspirated and cells were quickly washed twice
with ice-cold Hank’s balanced salt solution (HBSS) and harvested
with tripsin-EDTA. Cells were collected and radioactivity was
counted by a gamma-counter.
Statistical analysis
All the experiments were similarly done at least three times.
Most of the measurements were performed in triplicate and some
in duplicates. The statistical significance of differences between
two groups of data was analyzed by paired t-test and a P value
of,0.05 was considered significant. Unless indicated, the results
shown in the figures are representatives.
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